These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 12297138)

  • 1. Activated partial thromboplastin time is more sensitive than ecarin clotting time for monitoring low doses of desirudin.
    Mazoyer E; Drouet L; Delahousse B; Gruel Y; Rouyrre N
    Thromb Res; 2002 May; 106(4-5):271-2. PubMed ID: 12297138
    [No Abstract]   [Full Text] [Related]  

  • 2. Ecarin clotting time but not aPTT correlates with PEG-hirudin plasma activity.
    Moser M; Ruef J; Peter K; Kohler B; Gulba DC; Paterna N; Nordt T; Kübler W; Bode C
    J Thromb Thrombolysis; 2001 Oct; 12(2):165-9. PubMed ID: 11729368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monitoring of anticoagulant effects of direct thrombin inhibitors.
    Fenyvesi T; Jörg I; Harenberg J
    Semin Thromb Hemost; 2002 Aug; 28(4):361-8. PubMed ID: 12244483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Point-of-care ecarin clotting time versus activated clotting time in correlation with bivalirudin concentration.
    Casserly IP; Kereiakes DJ; Gray WA; Gibson PH; Lauer MA; Reginelli JP; Moliterno DJ
    Thromb Res; 2004; 113(2):115-21. PubMed ID: 15115666
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Follow-up of the treatment by direct thrombin inhibitors: activated partial thromboplastin time or ecarin clotting time].
    Kher A; Gouin I; Samama MM
    Ann Biol Clin (Paris); 2000; 58(5):575-9. PubMed ID: 11022100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A functional clotting assay to monitor the hirudin dosage.
    Zakir RM; Hoffman W; Bhatt BA; Spillert CR
    Blood Coagul Fibrinolysis; 2007 Mar; 18(2):119-23. PubMed ID: 17287627
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ecarin clotting time is sensitive to heparinoids: comparison of two different techniques.
    Demir M; Iqbal O; Untch B; Hoppensteadt DA; Gaikwad BS; Fareed J
    Clin Appl Thromb Hemost; 2001 Jan; 7(1):38-43. PubMed ID: 11190903
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The ecarin clotting time, a universal method to quantify direct thrombin inhibitors.
    Nowak G
    Pathophysiol Haemost Thromb; 2003 Jul-2004 Aug; 33(4):173-83. PubMed ID: 15583446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate.
    Douxfils J; Mullier F; Robert S; Chatelain C; Chatelain B; Dogné JM
    Thromb Haemost; 2012 May; 107(5):985-97. PubMed ID: 22438031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparing direct thrombin inhibitors using aPTT, ecarin clotting times, and thrombin inhibitor management testing.
    Gosselin RC; King JH; Janatpour KA; Dager WE; Larkin EC; Owings JT
    Ann Pharmacother; 2004 Sep; 38(9):1383-8. PubMed ID: 15238620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation of point-of-care ecarin clotting time versus activated clotting time with bivalirudin concentrations.
    Cho L; Kottke-Marchant K; Lincoff AM; Roffi M; Reginelli JP; Kaldus T; Moliterno DJ
    Am J Cardiol; 2003 May; 91(9):1110-3. PubMed ID: 12714157
    [No Abstract]   [Full Text] [Related]  

  • 12. Modified plasma-based ecarin clotting time assay for monitoring of recombinant hirudin during cardiac surgery.
    Choi TS; Khan AI; Greilich PE; Kroll MH
    Am J Clin Pathol; 2006 Feb; 125(2):290-5. PubMed ID: 16393689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biologic effects of recombinant hirudin (CGP 39393) in human volunteers. European Hirudin in Thrombosis Group.
    Verstraete M; Nurmohamed M; Kienast J; Siebeck M; Silling-Engelhardt G; Büller H; Hoet B; Bichler J; Close P
    J Am Coll Cardiol; 1993 Oct; 22(4):1080-8. PubMed ID: 8409044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transition from argatroban to oral anticoagulation with phenprocoumon or acenocoumarol: effects on prothrombin time, activated partial thromboplastin time, and Ecarin Clotting Time.
    Harder S; Graff J; Klinkhardt U; von Hentig N; Walenga JM; Watanabe H; Osakabe M; Breddin HK
    Thromb Haemost; 2004 Jun; 91(6):1137-45. PubMed ID: 15175800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monitoring of recombinant hirudin: assessment of a plasma-based ecarin clotting time assay.
    Pötzsch B; Hund S; Madlener K; Unkrig C; Müller-Berghaus G
    Thromb Res; 1997 Jun; 86(5):373-83. PubMed ID: 9211628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of ecarin chromogenic assay and prothrombinase induced clotting time in the monitoring of lepirudin for the treatment of heparin-induced thrombocytopenia.
    Guy S; Kitchen S; Laidlaw S; Cooper P; Woolley A; Maclean R
    Br J Haematol; 2008 Jul; 142(3):466-8. PubMed ID: 18510685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Use of ecarin clotting time in whole blood for monitoring recombinant hirudine treatment during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia].
    Devignes J; de Maistre E; Grosjean S; Walter AF; Hacquard M; Mulot A; Longrois D; Carteaux JP; Lecompte T
    Ann Biol Clin (Paris); 2005; 63(2):201-8. PubMed ID: 15771978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the aPTT with alternative tests for monitoring direct thrombin inhibitors in patient samples.
    Lind SE; Boyle ME; Fisher S; Ishimoto J; Trujillo TC; Kiser TH
    Am J Clin Pathol; 2014 May; 141(5):665-74. PubMed ID: 24713737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Measurement of patients' bivalirudin plasma levels by a thrombelastograph ecarin clotting time assay: a comparison to a standard activated clotting time.
    Carroll RC; Chavez JJ; Simmons JW; Snider CC; Wortham DC; Bresee SJ; Cohen E
    Anesth Analg; 2006 May; 102(5):1316-9. PubMed ID: 16632802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Laboratory testing of anticoagulants: the present and the future.
    Favaloro EJ; Lippi G; Koutts J
    Pathology; 2011 Dec; 43(7):682-92. PubMed ID: 22081129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.